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A B S T R A C T
Liver injury associatedwith exposure to therapeutic agents that undergo hepatic metabolism can involve
the formation of reactive metabolites. These may cause redox perturbation which can result in oxidative
stress as well as protein modiﬁcation leading to activation or inhibition of cellular transcriptional
responses. Nevertheless, the effects of these challenges on more than one transcriptional pathway
simultaneously remain unclear. We have investigated two transcription factors known to be sensitive to
electrophilic stress and redox perturbation, Nrf2 and NF-kB, in mouse liver cells. Cellular stress was
induced by the probes: N-acetyl-p-benzoquinineimine (NAPQI), the reactive metabolite of acetamino-
phen; dinitrochlorobenzene (DNCB), a model electrophile; and buthionine (S,R)-sulfoximine (BSO), an
inhibitor of glutamate-cysteine ligase. NAPQI, DNCB and BSO can all cause glutathione (GSH) depletion;
however only NAPQI and DNCB can covalently bind proteins. We also employed RNAi to manipulate
Keap1 (the inhibitor of Nrf2), Nrf2 itself and NF-kB-p65, to understand their roles in the response to drug
stress. All three chemicals induced Nrf2, but NF-kB binding activity was only increased after BSO
treatment. In fact, NF-kB binding activity decreased after exposure to NAPQI and DNCB. While RNAi
depletion of Keap1 led to reduced toxicity following exposure to DNCB, depletion of Nrf2 and NF-kB
augmented toxicity. Interestingly, increased Nrf2 caused by Keap1 depletion was reversed by co-
depletion of NF-kB.We demonstrate that Keap1/Nrf2 and NF-kB respond differently to electrophiles that
bind proteins covalently and the redox perturbation associated with glutathione depletion, and that
crosstalk may enable NF-kB to partly inﬂuence Nrf2 expression during cellular stress.
 2010 Elsevier Inc.
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Drug-induced liver injury (DILI) is a major cause of hospital
admissions [1], and one of the principal reasons for attrition of
new chemical entities [2]. For example, acetaminophen (APAP), a
commonly used analgesic known to induce liver injury on
overdose, accounts for the most common form of acute liver§ Financial support: This work was funded by theWellcome Trust [079674/Z/06/
Z], The University of Liverpool, The Overseas Research Students Award Scheme, and
Pﬁzer UK, as part of the Centre for Drug Safety Science supported by the Medical
Research Council [grant number G0700654].
Abbreviations: DILI, drug-induced liver injury; CRMs, chemically reactive metabo-
lites; GSH, glutathione; Nrf2, nuclear factor-erythroid 2 (NF-E2)-related factor; NF-
kB, NF-kappa B; ARE, anti-oxidant response element; NAPQI, N-acetyl-p-
benzoquinineimine; DNCB, dinitrochlorobenzene; BSO, buthionine (S,R)-sulfox-
imine; RNAi, RNA interference.
* Corresponding author. Tel.: +44 151 794 5979; fax: +44 151 794 5540.
E-mail addresses: C.E.P.Goldring@liverpool.ac.uk, chrissy@liv.ac.uk
(C.E. Goldring).
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Open access under CC BY license.failure in theUnited States [3]. A proportion of the pathogenesis of
DILI may occur through the generation of chemically reactive
metabolites (CRMs), usually formed through oxidative metabo-
lism of drugs by phase 1 enzymes [2]. CRMs can covalentlymodify
critical proteins, and bind to and deplete glutathione (GSH), the
predominant cellular redox buffer. This causes disturbance to the
cellular redox potential yielding a more oxidising environment
[4]. Although there are defense mechanisms present to counter
such disturbances [5], if the chemical challenge is overwhelming
and the defense is breached, a switch from cell defense to cell
death is favoured either by apoptosis or necrosis (for a review, see
[2]). Thus, a cell will defend itself where possible, but under
extreme conditions itmay allow itself to die. The ability of a cell to
respond to chemical stress occurs at least partially through the
activation of transcription factors. These transcription factors are
constitutively present in the cell or are rapidly synthesised when
needed, and they facilitate the upregulation of proteins implicat-
ed in cell defense or cell death. Two redox-sensitive transcription
factors, in particular, are the focus ofmuch interest in determining
the role of transcriptional adaption to chemical stress, namely
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kappa B (NF-kB).
Nrf2 plays a crucial role in cellular defense, and is the major
regulator of anti-oxidant response elements (AREs) present in the
regulatory region of themajority of cytoprotective genes [6]. Under
basal conditions, Nrf2 is sequestered by Keap1 in the cytoplasm
[7], and is constitutively targeted for ubiquitination by the Cul3-
dependent E3 ubiquitin ligase complex, which results in its
subsequent proteasomal degradation [8]. Under certain stress
conditions, such as exposure to electrophiles or an increase in
reactive oxygen species, it is believed that Keap1 undergoes a
conformational change, blocking Nrf2 ubiquitination and enabling
nuclear accumulation of Nrf2 and transactivation of ARE-depen-
dent genes.
Nuclear factor kappa-light-chain-enhancer-of activated B cells
(NF-kB) comprises ﬁve members belonging to the mammalian NF-
kB family, i.e., p65 (Rel A), RelB, c-Rel, p50/p105 (NF-kB1) and p52/
p100 (NF-kB2). NF-kB exists in the cytoplasmof unstimulated cells
as homo- or hetero-dimers, bound to a family of inhibitory proteins
known as IkB via non-covalent interactions. The predominant
hetero-dimer present in cells is p65/p50 dimer [9]. Upon
stimulation, the IkB kinase (IKK) complex which consists of a
complex with two subunits, IKKa and IKKb, and a regulatory
subunit, NF-kB essential modiﬁer (NEMO) [10], phosphorylates
IkB-a [11]. Upon phosphorylation, IkB-a is targeted for ubiqui-
tination and directed for proteasomal degradation [12]. This allows
the release of NF-kB and its nuclear accumulation resulting in the
transcription of genes involved in the inﬂammatory response, cell
proliferation, cell survival and to a limited degree, the anti-oxidant
response.
To date, there is little evidence for simultaneous regulation of
Nrf2 and NF-kB within cells and little is known about the
cellular consequences of such co-regulation. It may be valuable
to understand what is happening to both transcription factors
simultaneously to begin to understand the likely mechanisms
that occur when a cell is exposed to chemical stress. The
experiments presented here were designed to investigate the
functional outcome of chemical stress/protein modiﬁcation on
the transcription factors as well being informative of how the
cells actually sense these stresses. In this study, we hypothe-
sised that the balance between both transcription factors might
serve as a key cytoprotective mechanism to sense and respond
to cell stress, where activation or inhibition of NF-kB, or Nrf2, or
both transcription factors, may dictate the cellular response to
stress.
2. Materials and methods
2.1. Materials
All chemicals and reagents were obtained from Sigma–Aldrich
(Poole, UK), unless stated otherwise. Rabbit anti-mouse Nrf2 anti-
body was a kind gift from Professor John Hayes (Biomedical
Research Centre, University of Dundee).
2.2. Cell culture and treatment
Hepa-1c1c7 cells were maintained at 37 8C in a 5% CO2
atmosphere in Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Lonza, Wokingham, UK) supplemented with 584 mg/L L-gutamine,
10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100mg/ml
streptomycin. For all treatments, cells were incubatedwith serum-
free DMEM containing the indicated compound. All compounds
were dissolved in dimethyl sulfoxide (DMSO) at a ﬁnal concentra-
tion of the solvent in media of 0.1%, except for buthionine
sulfoximine (BSO), which was dissolved in water.2.3. RNA interference
Short interfering RNA (siRNA) duplexes targetingmouse Keap1,
and Nrf2 were purchased from Dharmacon (Lafayette, CO, USA)
and molecules targeting p65 were purchased from Invitrogen
(Paisley, UK). The siRNA duplexeswere as follows; si-Nrf2 sense 50-
GCA AGA AGC CAG AUA CAA A-30, anti-sense 50-U UUG UAU CUG
GCU UCU UGC-30, si-Keap1 sense 50-GCU AUG ACC CGG ACA GUG
A-30, anti-sense 50-U CAC UGU CCG GGU CAU AGC-30, si-p65 sense
50-UUC AUC UCC GGAGAG ACC AUUGGG A-30, anti-sense 50-U CCC
AAU GGU CUC UCC GGA GAU GAA-30. Hepa-1c1c7 were plated out
onto 96-well plates at 1  104 cells/well for NF-kB siRNA valida-
tion, 96-well plates at 7  103 cells/well for LDH assay, 24-well
plates at 5  104 cells/well for GSH assays and 10-cm dishes at
4  106 cells/dish for nuclear extractions. Cells were transfected
with 10 nM of siRNA directed against Keap1 or Nrf2, and 3 nM
siRNA against p65 for 48 h, using Lipofectamine 2000 (Invitrogen,
Paisley, UK) according to the manufacturer’s instructions.
2.4. Preparation of cytosolic and nuclear extracts and whole cell
lysates
For experiments with nuclear proteins, cells were treated with
NF-kB siRNA for 48 h or treated for 1 h with the chemicals under
investigation. Cytosolic and nuclear extracts were prepared using
the method of Dignam et al. [13]. For whole cell lysate
experiments, cells were treated with siRNA for 48 h and 6 h with
DMSO. After treatments, cells were lysed with radioimmunopre-
cipitation assay buffer. Total protein content was measured
according to the method of Bradford protein assay [14] with
commercial kit (Bio-Rad, Hemel Hempstead, UK) and samples
were stored at 80 8C before analysis.
2.5. Western immunoblotting
Cytosolic or nuclear extracts or whole cell lysates were resolved
by denaturing electrophoresis on pre-cast 4–12% Novex bis–tris
polyacrylamide gels (Invitrogen), using a 3-(N-morpholino)pro-
panesulfonic acid running buffer. Separated proteins were
transferred to Hybond nitrocellulose membranes (GE Healthcare
Life Sciences, Little Chalfont, UK), whichwere blocked for 15 min in
10% non-fat milk (Bio-Rad) in Tris-buffered saline (TBS, pH 7.0)
containing 0.1% Tween 20. Blocked membranes were probed with
rabbit anti-mouse Nrf2 (1:5000) in 10 ml of 2% bovine serum
albumin (BSA) for 1 h. After several washes, membranes were
probed with goat anti-rabbit (1:10000) horseradish peroxidase-
conjugated anti-IgG for 1 h. Western blots were visualised using
enhanced chemiluminescence (PerkinElmer, Beaconsﬁeld, UK) and
Hyperﬁlm (GE Healthcare Life Sciences). All blots were also probed
for actin (1:5000) as a loading control. Recombinant mouse His-
tagged Nrf2 (+con) was loaded as a standard to conﬁrm anti-body
speciﬁcity. Western blot band volumes were quantiﬁed using
TotalLab 100 software (Nonlinear Dynamics, Newcastle, UK) and
normalised against actin.
2.6. NF-kB electrophorectic mobility shift assay (EMSA)
AnNF-kBwild-type oligonucleotide (Wt) probe 50 to 30 strand:
(50-AGT TGAGGGGAC TTT CCCAGGC-30) was 50 end-labelledwith
adenosine 50-triphosphate [g-32P] ATP (PerkinElmer Life science,
Mechelen, Belgium) using T4 polynucleotide kinase (Promega
Corp, Madison WI, USA). Nuclear extracts (5 mg) were incubated
with labelled oligonucleotide in a binding buffer containing
(0.1 mg/ml) polydIdC (Amersham), 4% Ficoll, 20 mM HEPES,
35 mM NaCl, 60 mM KCl, NP40 0.01% and 2 mM dithiothreitol
(DTT) for 20 min at room temperature. The deﬁnition of a NF-kB
Fig. 1. Chemical stress activates Nrf2 and inhibits NF-kB. Cells were treated for 1 hwith NAPQI (A) or DNCB (B) and nuclear protein resolved on SDS-PAGE and probed for Nrf2.
NAPQI (A) and DNCB (B) activates Nrf2 nuclear accumulation dose-dependently. Actin is shown as loading control. Recombinant mouse His-tagged Nrf2 was loaded as a
positive control on the blot (+con). The bottom panel shows the densitometric analysis of Nrf2 positive bands normalised against actin. Paired t-test, *p < 0.05, ***p < 0.001.
Kruskal–Wallis, yp < 0.05, yyyp < 0.001. Cells were treated for 1 h with NAPQI (C) or DNCB (D) and nuclear protein was assayed using EMSA for NF-kB activity. NAPQI (C) and
DNCB (D) inhibit NF-kB binding activity dose-dependently. The assay was speciﬁc for the NF-kB protein as addition of a 50-fold excess of wild-type oligonucleotide (WT) to
the reaction displaced the bound protein from the radiolabelled oligonucleotide, while this was not observed with the addition of excess mutant (MT) oligonucleotide. The
addition of speciﬁc anti-NF-kB anti-body (p65), as opposed to non-speciﬁc anti-body (con Ab) to the binding reaction caused a supershift in the NF-kB band conﬁrming the
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Fig. 2. Depletion of glutathione activates Nrf2 and NF-kB. Cells were treated for 24 hwith BSO and lysed with 10 mMHCL. GSHwas depleted by amaximum of 80% of control
(A). Total GSH normalised against total protein content. Kruskal–Wallis, *p < 0.05, ***p < 0.001. Cells were treated for 24 h with BSO and nuclear protein was assayed for NF-
kB activity. BSO activates the translocation and binding of NF-kB dose-dependently (B). The assay was speciﬁc for the NF-kB protein as addition of a 50-fold excess of wild-
type oligonucleotide (Wt) to the reaction displaced the bound protein from the radiolabelled oligonucleotide, while this was not observed with the addition of excess mutant
(Mut) oligonucleotide. The addition of speciﬁc anti-NF-kB anti-body (p65), as opposed to non-speciﬁc anti-body (con Ab) to the binding reaction caused a supershift in the
NF-kB band conﬁrming the composition of the NF-kB complex. The data shows the densitometric analysis of NF-kB normalised against control. Kruskal–Wallis, *p < 0.05.
Cells were treated for 24 hs with BSO and nuclear protein resolved on SDS-PAGE and probed for Nrf2. BSO activates Nrf2 nuclear accumulation dose-dependently (C). Actin is
shown as loading control. Recombinant mouse His-tagged Nrf2 was loaded as a positive control on the blot (+con). The bottom panel shows densitometric analysis of Nrf2
normalised against actin. Cells were treated for 24 h with BSO. LDH assay shows minimal leakage upon treatment with BSO (D). Extracellular LDH activity is expressed as a
percentage of total (extracellular plus intracellular) LDH activity. In all experiments, the control cells were treated with 0.1% DMSO.
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supershift assays using NF-kB speciﬁc anti-bodies, addition of
mouse anti-p65 and/or anti-p50 (Santa Cruz) and a control non-
speciﬁc anti-body. For competition assays, unlabelled wild-type
or mutant (50-AGT TGA GGC GAC TTT CCC AGG C-30) oligonucleo-
tides were added in excess for 10 min prior to addition of labelled
oligonucleotide. Protein–DNA complexes were resolved by non-
denaturing electrophoresis on a 5% polyacrylamide gel for 1.5 h at
200 V in 0.5 Tris–Borate–EDTA buffer. Gels were subsequently
dried and exposed to a Phosphor Imager screen (Molecular
Dynamics, Sunnyvale, CA). The gels were visualised and
bands were quantiﬁed using ImageQuant software (Molecular
Dynamics).
2.7. Confocal microscopy
Hepa-1c1c7 cells were plated out on Lab-Tek II chamber slides
(Nalge Nunc, Rochester, NY) at 2.5 105 cells/chamber for 24 h.
Following treatment, cells were washed in phosphate buffered
saline (PBS) and ﬁxed in 4% paraformaldehyde at 4 8C for 30 min.composition of the NF-kB complex. The data demonstrate the densitometic analysis of N
treated for 1 h with NAPQI (E) or DNCB (F) and lysed with 10 mM HCL. GSH depletion r
highest dose of DNCB (F). Total GSH normalised against total protein content. Kruskal–W
24 hwith NAPQI (H). LDH assay showsminimal leakage upon treatmentwith NAPQI (whi
with NAPQI (white) or DNCB (black) (H) after 24 h. Extracellular LDH activity is express
ANOVA, ***p < 0.001, yp < 0.05, yyyp < 0.001. In all experiments, the control cells wereFixed cells were permeabilised with 0.2% Triton X-100, quenched
with 100 mM glycine and blocked with 10% FBS, for 10 min each.
Cells were then incubated with rabbit anti-mouse Nrf2 or
monoclonal anti-mouse p65 (1:500) in 2% FBS at 37 8C for 1 h.
Following several washes in PBS, cells were incubated with FITC-
conjugated goat anti-rabbit or FITC-conjugated goat anti-mouse
(1:250) in 2% FBS at 37 8C for 1 h. Cells were washed several times
with PBS and nuclei were counter-stained with Hoechst 33258
(2mg/ml) (Invitrogen) in PBS at room temperature for 10 min.
Chambers were detached from the slides and coverslips were
mounted usingVectashield hard-setmedium (Vectorlabs, Peterbor-
ough, UK). Immunoﬂuoresence was visualised using a Leica SP2
AOBS confocalmicroscope (LeicaMicrosystems,MiltonKeynes, UK).
2.8. Measurement of lactate dehydrogenase leakage
Hepa-1c1c7 cells were plated out on 96-well plates at
2  104 cells/well for 24 h. Following treatment, lactate dehydro-
genase (LDH) leakagewasmeasured using a Cytotoxicity Detection
Kit (Roche Applied Science, Burgess Hill, UK) in accordance withF-kB normalised against control. Kruskal–Wallis, *p < 0.05, ***p < 0.001. Cells were
eaches 80% of control with the highest dose of NAPQI (E) and 100% of control with
allis, **p < 0.01, ***p < 0.001. Cells were treated for 1 h with NAPQI or DNCB (G) and
te) or DNCB (black) for 1 h (G). LDH assay shows substantial leakage upon treatment
ed as a percentage of total (extracellular plus intracellular) LDH activity. One-way
treated with 0.1% DMSO.
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culturemedium (extracellular) is expressed as a percentage of total
LDH (intracellular plus extracellular).
2.9. Measurement of glutathione
Hepa-1c1c7 cells were plated out on 24-well plates at
2  105cells/well for 24 h. Total GSH content was quantiﬁed using
the 5,5-O-dithiobis(2-nitrobenzoic acid) –GSH reductase recycling
method, as previously described by Vandeputte et al. [15]. Sample
GSH concentrations were calculated via reference to a standard
curve ranging from 0 to 50 nmol/ml GSH. The GSH concentration
for each sample was normalised to total protein content.
2.10. Data analysis
Data are expressed as mean  standard deviation of the mean.
The signiﬁcance of differences within the data was assessed by
Kruskal–Wallis analysis of variance (ANOVA), one-way ANOVA or
Student’s t-test. A difference was considered signiﬁcant at p < 0.05.Fig. 3. Subcellular localisation of p65 (A) and Nrf2 (B) in Hepa-1c1c7 cells exposed to cont
ii and iii), FITC-conjugate goat anti-Nrf2 (B)(i, ii and iii) and Hoechst 33258 (A)(B)(iv, v3. Results
3.1. N-acetyl-p-benzoquinoneimine (NAPQI) and
dinitrochlorobenzene (DNCB) activate Nrf2 but inhibit NF-kB activity
In common with all mammalian hepatoma cell lines, Hepa-
1c1c7, lacks metabolic competence and therefore cannot directly
bioactivate acetaminophen. Consequently, NAPQI, the chemically
reactive metabolite of acetaminophen [16], was used in these
studies along with DNCB, a model alkylating agent and contact
sensitizer [17]. Both have been previously shown to deplete GSH
and covalently bind cellular proteins [18–22]. Following a 1 h
exposure, nuclear accumulation of Nrf2 increased with increasing
concentrations of NAPQI (Fig. 1A) and DNCB (Fig. 1B); an increase
in Nrf2 after exposure to NAPQI or DNCB has been demonstrated
previously in our lab [18]. Immunochemical analysis of Nrf2 and
NF-kB-p65 cellular localisation shows an increase in NF-kB-p65
cellular abundance (Fig. 3A, second panel) and a clear increase in
Nrf2 (Fig. 3B, second panel) accumulation in the nucleus after 1 h of
DNCB treatment. These cells consistently express low butrol and DNCB or BSO for 1 and 24 h, respectively. FITC-conjugate goat anti-p65 (A)(i,
and vi) immunoﬂuorescence were visualised by confocal microscopy.
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however on the contrary to Nrf2 expression, NF-kB DNA binding
decreased with increasing concentrations of NAPQI (Fig. 1C) and
DNCB (Fig. 1D). Both chemicals caused a depletion of total GSH,
which fell to 20% of the control at the highest dose of NAPQI
(Fig. 1E) and to undetectable levels at the highest dose of DNCBFig. 4. Effect on Nrf2, NF-kB and GSH by treatment of cells with NAPQI, DNCB and BSO. N
binding activity concurrently with GSH depletion. BSO (C) increased both Nrf2 nuclear ac
have been omitted from graphs for visual clarity.(Fig. 1F). Lactate dehydrogenase (LDH) leakage assays show
limited leakage after exposure of cells to test compounds for
1 h, although this is signiﬁcant at 300 mM of NAPQI (Fig. 1G). The
assay demonstrates substantial toxicity at 24 h following exposure
to concentration of NAPQI at 100 and 300mM, andwith DNCB at all
concentration between 10 and 100 mM (Fig. 1H).APQI (A) and DNCB (B) increased Nrf2 nuclear accumulation and decreased NF-kB
cumulation and NF-kB binding activity concurrently with GSH depletion. Error bars
A.J.L. Chia et al. / Biochemical Pharmacology 80 (2010) 410–4214163.2. Glutathione depletion activates both Nrf2 and NF-kB activities
We then examined whether GSH depletion and/or the protein
covalent modiﬁcation due to the electrophilic nature of these
compounds was responsible for the different effects observed on
these pathways. We therefore used L-buthionine(S,R)-sulfoximine
(BSO), which depletes intracellular GSH efﬁciently by irreversible
inhibition of the rate-limiting enzyme of GSH synthesis, GCLC [23].
It is now well-accepted that depletion of GSH due to exposure of
cells to BSO leads to redox perturbation in a variety of cell models,
for recent examples see [24,25]. BSO concentrations of 3 to 30 mM
depletes GSH after 24 h exposure (Supplementary Fig 1A), but does
not induce NF-kB binding activity (Supplementary Fig 1B).
However, 100–500mM of BSO increased NF-kB binding activity
(Fig. 2B) and increased nuclear accumulation of Nrf2 (Fig. 2C),
which correspond with GSH levels being depleted to below 20% of
the basal level (Fig. 2A); a BSO-mediated increase in Nrf2 has been
seen previously in our lab [18]. Immunochemical analysis of Nrf2
andNF-kB cellular localisation after 24 h of BSO exposure indicates
some cellular accumulation of NF-kB (Fig. 3A, third panel) andFig. 5. RNAi modulation of Nrf2, Keap1 and p65 inﬂuences cell defense. Cells were transf
DNCB toxicity (A). Nrf2 (B) and p65 (C) depletion increased DNCB toxicity. Keap1 and p65
p65 (D). The change in IC50 of each RNAi treatment is expressed in (E). Extracellular LDH
activity versus si-neg control treated with 100uM DNCB. All data compared to their resp
Nrf2 versus si-neg and zp < 0.05 si-p65 versus si-neg. In all experiments, the control csubstantial nuclear accumulation of Nrf2 (Fig. 3B, third panel). 24 h
exposure to BSO does not cause toxicity in the cells (Fig. 2E).
3.3. Comparison of Nrf2 and NF-kB regulation by NAPQI, DNCB and
BSO
The effect of treatment with NAPQI, DNCB or BSO on Nrf2 and
NF-kB activity can be seen clearly in double-y graphs (Fig. 4).
NAPQI (Fig. 4A) and DNCB (Fig. 4B), which can covalently bind
proteins and deplete GSH, increased Nrf2 activity and decreased
NF-kB binding activity, while the GSH-depleting agent, BSO
(Fig. 4C), increased both Nrf2 and NF-kB activity.
3.4. RNA interference modulates Keap1, Nrf2 and NF-kB, p65 subunit
expression
RNAi is a conserved mechanism of speciﬁc gene silencing
through posttranslational degradation of mRNA [26]. In this study,
we used RNAi to investigate the physiological and molecular
effects of Keap1, Nrf2 and p65 silencing on cellular cytoprotection.ected for 48 h with RNAi and treated for 6 h with DNCB. Keap1 depletion decreased
co-depletion shows the effect of Keap1 knock down alone is reversed by depletion of
activity is expressed as a percentage of total (extracellular plus intracellular) LDH
ective negative controls. Paired t-test, *p < 0.05, si-keap1 versus si-neg, yp < 0.05 si-
ells were treated with 0.1% DMSO.
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molecules used resulted in 80% silencing of each protein [18]. RNAi
directed against NF-kB, p65 subunit expression was also success-
ful. A 70% reduction in basal NF-kB p65 expression was detected in
cells treated with p65 RNAi (Supplementary Fig 2A) concurrently
with a decrease in nuclear NF-kB DNA-binding activity (Supple-
mentary Fig 2B).
3.5. RNAi modulation of Nrf2, Keap1 and p65 inﬂuences cell defense in
hepa-1c1c7 cells
Modulation of Nrf2, Keap1 and NF-kB, p65 had a profound
effect on the ability of Hepa-1c1c7 cells to elicit a defense
response against chemical stress. DNCB was again used as a
model electrophile to induce chemical stress. LDH assays
indicated that RNAi knock down of Keap1 (Fig. 5A) protects
the cells against DNCB toxicity and shows that DNCB toxicity was
augmented when Nrf2 was depleted with RNAi directed against
Nrf2 (Fig. 5B) and p65 was depleted (Fig. 5C) individually.
Interestingly, the phenotypic effect of the Keap1 knock downwas
reversed when both Keap1 and p65 (Fig. 5D) were depleted
simultaneously. The IC50s of the siRNA treatments compared to
their respective negative controls show that Keap1 silencing
causes a 20 mM increase in IC50, Nrf2 silencing causes a 18uM
decrease in IC50, si-p65 causes a 4 mM decrease in IC50 and si-
Keap1 + p65 knock down leads to a 5 mM decrease in IC50
(Fig. 5E).Fig. 6. RNAimodulation of Nrf2, Keap1 and p65 inﬂuences the level of GSH. Cells were tran
basal GSH levels (A). Nrf2 depletion caused a decrease in basal GSH level (B). With p65 de
depleted simultaneously, there is no increase in basal GSH levels (D). Total GSH norm
compared to their respective negative controls (si-neg). Kruskal–Wallis ANOVA, *p < 0.05
versus si-neg. In all experiments, the control cells were treated with 0.1% DMSO.3.6. RNAi depletion of Nrf2 and Keap1, but not p65, inﬂuences the
basal level of GSH in hepa-1c1c7 cells
We thenmeasured the effect of modulation of Nrf2, Keap1 and
p65 on the basal level of GSH to determine whether the GSH level
has an inﬂuence on the toxicity seen with DNCB. Keap1 silencing
increased the basal level of GSH by approximately 40% and at
10 mM of DNCB, the GSH level increased by an additional 20%
(Fig. 6A). Nrf2 silencing decreased the basal level of GSH by
approximately 20% and at 20mM of DNCB, there is a clear
decrease in GSH levels to less than 20% of total GSH (Fig. 6B). p65
RNAi did not affect the basal level of GSH or levels after treatment
with DNCB (Fig. 6C). Interestingly, in the presence of Keap1 and
NF-kB-p65 RNAi, there is no increase in the basal GSH level
(Fig. 6D).
3.7. Simultaneous depletion of Keap1 and NF-kB-p65 by RNAi
inﬂuences the basal level of Nrf2 in hepa1c cells
In order to investigate the possible inﬂuence of NF-kB-p65 on
the activity of Nrf2, the effect of RNAi depletion of NF-kB-p65 on
Nrf2 expression was determined in Hepa-1c1c7 cells. p65 RNAi
alone had no effect on the cellular expression of Nrf2, however,
when co-transfected with Keap1 RNAi, p65 depletion was able to
reverse the induction of Nrf2 caused by Keap1 depletion (Fig. 7).
This suggests that p65 plays a role in the modulation of Nrf2
expression.sfected for 48 hwith RNAi and treated for 6 hwith DNCB. Keap1 depletion increases
pletion there is no change in GSH level basally (C). Where of both Keap1 and p65 are
alised against total protein content versus si-neg control untreated. All data are
si-keap1 versus si-neg, yp < 0.05 si-Nrf2 versus si-neg and zp < 0.05 si-Keap1 + p65
Fig. 7. Simultaneous RNAi modulation of Keap1 and p65 inﬂuences the level of Nrf2 protein. Cells were transfected for 48 h with RNAi. Whole cell lysates were resolved on
SDS-PAGE and probed for Nrf2. Keap1 depletion increases basal Nrf2 and the depletion of Nrf2 decreases basal Nrf2. p65 depletion does not change Nrf2 basally in the cells.
The depletion of Keap1 and p65 simultaneously reduces the expression of Nrf2 basally. All data are compared to their respective controls. Actin is shown as loading control.
Recombinant mouse His-tagged Nrf2 was loaded as a positive control on the blot (+con). The bottom panel shows the densitometric analysis of Nrf2 normalised against actin.
One-way ANOVA, **p < 0.01, ***p < 0.001.
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The roles of the NF-kB pathway in cellular survival, prolifera-
tion and the inﬂammatory response and of the Nrf2/Keap1
pathway in the cellular defense against chemical stress and redox
perturbation are well described. However, it is still unclear as to
how both pathways simultaneously respond to these latter
insults. In our study, both chemical stress and GSH depletionwith
associated redox perturbation induced Nrf2, detected as nuclear
accumulation observed by confocal microscopy and Western
blotting (Fig. 3). Chemical stress induced by exposure to DNCB
caused a decrease in NF-kB binding activity (Fig. 1D) despite the
cellular accumulation of NF-kB-p65 (Fig. 3A). On the other hand,
redox perturbation that ensues from the GSH-depleting action of
BSO activates nuclear translocation of Nrf2 as well as causing
increased DNA-binding activity of NF-kB (Figs. 1 and 2). This is
consistent with the notion that Nrf2 can be activated through
covalent modiﬁcation as well as GSH depletion. In the case of NF-
kB, activity can either be enhanced by GSH depletion, or inhibited
by reactive chemical exposure, through cysteine modiﬁcation by
covalent binding to one or more subunits in NF-kB, or to other
factors that regulate NF-kB. Here we have observed that NAPQI
and DNCB inhibits NF-kB DNA activity, but the question as to
whether both chemicals control NF-kB through an upstream
effect or by directly interfering with its activity is unclear and
hence further investigation is needed. For both transcription
factors, nevertheless, it should be noted that a deﬁnitive link
between critical cysteine(s) modiﬁcation, which may be irrevers-
ible or reversible, as a consequence of covalent binding or GSH
depletion, and a change in activity still remains to be determined
experimentally.
Our observations are in agreement with previous studies in
animal and cell-based models that showed that NAPQI induces theactivation of Nrf2 [18,27] and inhibits NF-kB DNA-binding activity
[28]. BSO depletes GSH by binding to the active site of GCLC non-
covalently, inhibiting the activity of GCLC [23]. In our cell-based
model, we have shown that depletion of GSH by BSO induces the
nuclear accumulation of Nrf2 and increases NF-kB binding
concurrently (Fig. 2). The depletion of GSH over 24 h by BSO does
not elicit cytotoxicity (Fig. 2D). This is in agreement with our
previous ﬁnding in which BSO induced nuclear accumulation of
Nrf2 [18] and ﬁndings by others in which BSO induced NF-kB
activity [29,30]. It should be emphasized that the induction of Nrf2
and NF-kB by BSO only occurs if the depletion of GSH is to below
20% of total cellular GSH at 100 mM, which may be the threshold
level to induce both transcription factors. In addition, both of the
Nrf2 and NF-kB responses to NAPQI, DNCB and BSO occur at
concentrations where toxicity is not or has not yet become
apparent, hence these factors appear to be able to sense and
respond before toxicity emerges.
It has been shown previously that 15-deoxy-D12, 14-
prostaglandin J2 (15d-PG J2), an endogenous cyclopentenone
prostaglandin molecule which can exert a powerful anti-
inﬂammatory activity, is able to induce Nrf2/Keap1 and inhibit
NF-kB [31,32]. While 15d-PGJ2 is able to directly bind to Keap1
thiol residues and induce Nrf2, without the depletion of GSH
[18,33], NF-kB binding activity can be inhibited by 15d-PGJ2
through the direct modiﬁcation of the p65 subunit [32].
Therefore, it is becoming clear that exogenous or endogenous
compounds possessing the potential for protein covalent binding
display very different effects on the Nrf2/Keap1 and NF-kB
pathways, whereas agents such as BSO that deplete GSH– may
have similar effects on both redox-sensitive transcription factors.
Hence, these factors may serve as sensors to different types of
stress, allowing cells to adapt and respond in a different but
appropriate manner.
Fig. 8. Proposed regulation of Nrf2 and NF-kB by protein modiﬁcation or GSH depletion. (This scheme is based upon data derived in this study and other work ([18,27–
30,42])). Protein covalent modiﬁcation associated with exposure to chemically reactive metabolites activates Nrf2 inducing the transcription of cytoprotective proteins.
However, protein covalent modiﬁcation inhibits NF-kB, thereby reducing the transcription of anti-apoptotic and anti-oxidant proteins. This leads to cellular protection
through the Nrf2 pathway, but if the protection is overwhelmed, cell death may ensue due to inhibition of NF-kB. GSH depletion without covalent modiﬁcation will cause
intracellular redox perturbation, activation of both Nrf2 and NF-kB, inducing the transcription of cytoprotective proteins, and anti-apoptotic and anti-oxidant proteins,
respectively. This may lead to cellular protection against the potentially damaging effects of redox perturbation.
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validity of experiments such as those in the present study, is the
fact that a reactive metabolite (in this case NAPQI) is added
exogenously to cells rather than being generated endogenously.
The necessity to add a reactive metabolite outside of the cell
remains a major hurdle in attempting to study the molecular
pathways elicited by exposure of cells to drugs that require
bioactivation. Nevertheless, data from this laboratory addressing
the reactivity of residues in several proteins (i.e. GST-P and Keap1 –
the regulator of Nrf2) show that these proteins demonstrate
similar proﬁles of cysteine reactivity, as assessed by mass
spectrometry, whether the protein is present at endogenous levels
(GST-P) or is over-expressed (Keap1), to the proﬁle of NAPQI
binding to the recombinant proteins in vitro [18,34]. Therefore,
while there are certainly limitations that need to be considered
when a reactive metabolite is added exogenously to a cell rather
than generated intracellularly, for certain reactive metabolites the
proﬁles of modiﬁcation outside and inside a cell may be similar.
BothNrf2 andNF-kB play important roles in cellular defense, by
inducing anti-oxidant enzymes, phase II enzymes and anti-
apoptotic proteins. Co-regulation has not been shown before,
therefore we have attempted to explore the consequences of such
co-regulation by studying the effect ofmodulating the level of each
transcription factors pathway both separately and simultaneously.
Using RNAi with DNCB as a model electrophile, we show here thatan increase in cellular Nrf2, caused by Keap1 silencing, shifts the
DNCB toxicity curve to the left, demonstrating increased resistance
to DNCB toxicity. Conversely, decreased Nrf2 protein expression
resulted in an increased susceptibility to DNCB toxicity. These
ﬁndings support previous data [18] and emphasize the importance
of Nrf2 in cellular defense. From our data, p65 does not appear to
play a signiﬁcant role in cell protection since si-p65 reduced the
DNCB IC50 by only 4 mM. To better understand the role of each
transcription factor individually and in concert with respect to cell
defense and protection, we used RNAi simultaneously against
Keap1 and p65, in order to: (1) monitor how changes in one
transcription factor pathway alters the response mediated by the
other pathway and (2) to attempt to model using this molecular
genetics approach what we have observed in the cell during the
response of Nrf2 and NF-kB to chemical stress elevated by DNCB.
As predicted, depletion of Keap1, the inhibitor of Nrf2, increased
cellular defense. The co-transfection of RNAi against Keap1 and
p65 reversed the phenotypic effect seen with individual Keap1
knock down (Fig. 5D). The protective effect of Nrf2 induction
caused by the loss of Keap1 was reduced when p65 was depleted,
implying a role for p65 as a modulator of Nrf2-dependent cell
protection. Therefore, our data suggest that modulation of p65 has
an effect on the ability of the cell to defend against toxicity via the
Nrf2/Keap1 pathway, and that the Nrf2 and NF-kB pathways are
linked.
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and endogenous oxidative stress. Therefore, we examined if the
depletion of Keap1, Nrf2 and p65 has any effect on the basal level of
GSH thus further inﬂuencing the cells’ ability to defend against
electrophile toxicity. We have demonstrated that the depletion of
Keap1 increases the basal level of GSH (Fig. 6A), and depletion of
Nrf2 decreases the basal level of GSH (Fig. 6B). This is consistent
with the evidence that Nrf2 is one of the main regulators of GSH
synthesis [18,35–37]. RNAi depletion of p65 has no effect on the
level of GSH basally or in the presence of DNCB (Fig. 6C). We have
shown that co- modulation of Keap1 and p65 affects the cell’s
ability to defend against DNCB toxicity. Interestingly, the
simultaneous depletion of p65 and Keap1 prevented the increase
in basal levels of GSH (Fig. 5D) seen with Keap1 knock down only.
In line with this we have shown that the expression of Nrf2 was
reduced by the co-depletion of Keap1 and p65 (Fig. 7). The decrease
in basal Nrf2 protein expression may explain the reverse in DNCB
toxicity protection and the reduction of basal GSH by Keap1
depletion. Therefore, these observations imply that p65 may play
an important role in the expression and the function of Nrf2 and
further work is required to fully test this hypothesis.
The results of this study, indicating crosstalk between the Nrf2
and NF-kB pathways support evidence from other groups
demonstrating that the GSH rate-limiting synthetic enzyme, GCLC,
is regulated by Nrf2 indirectly through NF-kB [38–40]. Recently, it
has also been shown that Keap1 is able to interact directly with
IKKb and to promote its proteasomal degradation via ubiquitina-
tion in human cells [41]. In this study, overexpression of Keap1was
seen to repress TNF-a induced NF-kB activity, while the depletion
of Keap1 by RNAi induced the nuclear accumulation and activity of
NF-kB. This suggests that Keap1 not only plays an important role in
regulating Nrf2 but may also be a key regulator of the NF-kB
pathway.
In conclusion, we have demonstrated that the transcription
factors, Nrf2/Keap1 andNF-kB, respond differently to arylating and
GSH-depleting agents. During chemical stress, it is likely that the
cell attempts to protect itself by activating Nrf2, inducing a
pleiotropic transcriptional response of cytoprotective proteins.
However, when this protective mechanism is overwhelmed and
cellular damage is too great, it may be more beneﬁcial for the cells
to undergo apoptotic cell death due to the inhibition of NF-kB.
During redox perturbation, to which the cell is constantly exposed
under physiological conditions, activation of both Nrf2 and NF-kB
may occur to protect the cells and prevent further damage (Fig. 8).
Nonetheless, protein modiﬁcation by chemical arylation or
oxidation as a consequence of GSH depletion on other signal
transduction pathways involved in cellular protection or toxicity
needs to be examined. Also, the use of GSH modulators such as N-
acetylcysteine and GSH ester, or GSH depletors such as diethyl-
maleate and phorone, and the measurement of oxidative stress
using chemical probes should be considered in future investiga-
tions. Our results also suggest a crosstalk between Nrf2/Keap1 and
NF-kB pathways, where p65 was shown to modulate the
expression and functionality of Nrf2. More work is required to
fully deﬁne the emerging links between the Nrf2/Keap1 and NF-kB
pathways, and how these impact on cellular response to drug
exposure.
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